Xeris Biopharma Holdings (XERS) Other Operating Expenses (2020 - 2026)

Xeris Biopharma Holdings' Other Operating Expenses history runs 7 years deep, the most recent figure standing at $13.3 million for Q1 2026.

• Quarterly Other Operating Expenses rose 16.14% year-over-year to $13.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.3 million (up 9.57% YoY) and the FY2025 annual result came in at $53.4 million, up 12.03% from the prior year.
• Other Operating Expenses was $13.3 million for Q1 2026 at Xeris Biopharma Holdings, down from $13.7 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $16.3 million in Q3 2024 and bottomed at $7.5 million in Q2 2022.
• A 5-year average of $11.0 million and a median of $10.5 million in 2024 frame the typical range for Other Operating Expenses.
• Annual changes were most pronounced in 2022 — Other Operating Expenses surged 392.0% — and 2025, when it dropped 15.93%.
• Xeris Biopharma Holdings' Other Operating Expenses stood at $9.0 million in 2022, then gained by 14.21% to $10.3 million in 2023, then gained by 18.56% to $12.2 million in 2024, then advanced by 12.05% to $13.7 million in 2025, then retreated by 2.74% to $13.3 million in 2026.
• Business Quant data shows XERS's Other Operating Expenses at $13.3 million in Q1 2026, $13.7 million in Q4 2025, and $13.7 million in Q3 2025.